Loading organizations...
§ Private Profile · Waltham, MA, USA
Metamark Genetics is a company.
Metamark Genetics has raised $35.0M across 2 funding rounds.
Key people at Metamark Genetics.
Metamark Genetics has raised $35.0M in total across 2 funding rounds.
Metamark Genetics develops advanced diagnostic and prognostic tests, primarily for prostate cancer. The company utilizes a proprietary proteomics platform, creating assays that offer critical insights into disease progression and treatment response. These specialized tests inform personalized treatment planning, enhancing patient stratification and guiding therapeutic decisions precisely.
Founded in 2007, Metamark Genetics originated from the scientific vision of Dr. Lynda Chin, a key scientific founder. Its inception was driven by the urgent need for precise diagnostic tools to enable personalized cancer care. Dr. Chin's expertise in cancer genomics shaped the development of innovative, function-based prognostic assays, aiming to improve patient outcomes.
Metamark Genetics' diagnostic products serve clinicians and patients, providing enhanced information for critical treatment decisions. The company's vision is to advance cancer care through next-generation diagnostic and prognostic testing. They aspire to transform clinical cancer management by delivering actionable molecular insights, facilitating effective, tailored therapies throughout the patient journey.
Metamark Genetics has raised $35.0M across 2 funding rounds. Most recently, it raised $13.0M Series B in November 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 5, 2012 | $13M Series B | — | — | Announced |
| Jul 13, 2010 | $22M Series B | — | — | Announced |
Metamark Genetics is a privately-held biotechnology company specializing in advanced diagnostics and prognostics for urological cancers, particularly prostate cancer.[1][2] It develops novel, function-based tests to enable more informed treatment decisions and promote personalized patient care, serving patients, caregivers, and healthcare professionals through a mix of traditional and proprietary products that address the full diagnostic and therapeutic journey.[1][2]
The company focuses on comprehensive urological cancer care, combining deep urology expertise with cutting-edge technology like the Metamark Advantage platform to shift treatment paradigms toward precision medicine.[2] This positions Metamark as a key player in oncology diagnostics, improving outcomes by providing high-quality products, dedicated customer service, and exclusive prognostics for clinicians.[2]
Metamark Genetics was founded as a biotechnology firm dedicated to creating innovative prognostic and diagnostic tests for cancer, with an early emphasis on function-based approaches to enhance patient outcomes.[1] While specific founding year and founder details are not detailed in available sources, the company emerged in the biotech landscape to tackle unmet needs in cancer diagnostics, particularly urology.[1][2]
Its evolution centers on urological cancers, building traction through proprietary technologies that integrate with traditional diagnostics for prostate cancer management—a pivotal focus given the prevalence and complexity of the disease.[2] Early development likely hinged on advancing tests that go beyond standard methods, establishing Metamark as a leader in personalized care amid growing demand for precision oncology tools.[1][2]
Metamark Genetics rides the wave of precision oncology, where genomic and function-based diagnostics are transforming cancer care amid rising prostate cancer incidence and demands for personalized medicine.[1][2] Timing aligns with biotech advances in targeted therapies, as market forces like aging populations and improved sequencing tech favor companies delivering actionable insights over broad screenings.[1]
It influences the ecosystem by bridging diagnostics and treatment, supporting clinicians in genitourinary oncology and contributing to trends seen in related firms like Nuvation Bio, which target difficult cancers via novel candidates.[3] This positions Metamark favorably in a landscape shifting toward integrated urology solutions, amplifying impact through tech-enabled prognostic tools.[2]
Metamark Genetics is poised to expand its Metamark Advantage footprint, potentially integrating with emerging drug conjugates and AI-driven analytics to deepen prostate cancer personalization.[2][3] Trends like oncology pipeline acceleration—evident in peers advancing BET inhibitors and precision trials—will shape its path, enhancing prognostic accuracy amid regulatory pushes for companion diagnostics.[3]
Its influence may evolve by partnering with pharma leaders, scaling urology expertise globally, and riding biotech funding cycles focused on unmet cancer needs, solidifying its role from diagnostics innovator to ecosystem enabler—echoing its founding mission to redefine cancer care.[1][2]
Key people at Metamark Genetics.
Metamark Genetics has raised $35.0M in total across 2 funding rounds.
